论文部分内容阅读
目的 评价替尼泊甙的临床应用价值。方法 多中心协作研究 ,观察单药及联合用药治疗152例晚期小细胞肺癌 (SCLC)、恶性淋巴瘤与脑瘤的疗效与毒性反应。结果 替尼泊甙单药组对SCLC及恶性淋巴瘤的有效率分别为 4 3 8%与 4 2 8% ,主要副作用为白细胞减少、胃肠道反应等。联合化疗组又分为研究组 (用国产替尼泊甙 )与对照组 (用威猛作对照 )、对SCLC与淋巴瘤的有效率分别为 77 4 %及 6 8 3% (P >0 0 5)。替尼泊甙联合化疗对脑瘤的有效率为 4 6 2 % ,其中对脑胶质瘤的有效率为 52 6 %。结论 国产替尼泊甙与进口威猛的疗效和毒性反应相似 ,值得临床推广应用。
Objective To evaluate the clinical application of teniposide. Methods A multicenter collaborative study was conducted to observe the efficacy and toxicity of single-agent and combination therapy in 152 patients with advanced small cell lung cancer (SCLC), malignant lymphoma, and brain tumor. Results The efficacy of teniposide monotherapy for SCLC and malignant lymphoma was 43.8% and 42.8%, respectively. The main side effects were leucopenia and gastrointestinal reactions. The combined chemotherapy group was divided into study group (with domestic teniposide) and control group (with WM as control), and the effective rates for SCLC and lymphoma were 77 4 % and 683 % respectively (P >0 0). 5). The effective rate of teniposide combined with chemotherapy for brain tumors was 462%, and the effective rate for glioma was 52.6%. Conclusion The efficacy and toxicological response of domestic teniposide and imported mighty are similar and worthy of clinical application.